Drug Approval | December 11, 2025
Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Captured microbes are then neutralized on engineered microbicidal surfaces
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
The fresh capital will propel Cordance into its first-in-human clinical trial
Millions of stroke survivors across the world may soon have a new defense
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Subscribe To Our Newsletter & Stay Updated
